Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Homology Medicines, Inc. | fixx-ex322_8.htm |
| EX-32.1 - EX-32.1 - Homology Medicines, Inc. | fixx-ex321_9.htm |
| EX-31.2 - EX-31.2 - Homology Medicines, Inc. | fixx-ex312_11.htm |
| EX-31.1 - EX-31.1 - Homology Medicines, Inc. | fixx-ex311_7.htm |
| EX-10.9 - EX-10.9 - Homology Medicines, Inc. | fixx-ex109_1019.htm |
| EX-10.5 - EX-10.5 - Homology Medicines, Inc. | fixx-ex105_902.htm |
| EX-4.4 - EX-4.4 - Homology Medicines, Inc. | fixx-ex44_1018.htm |
| 10-K - 10-K - Homology Medicines, Inc. | fixx-10k_20191231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-230664 on Form S-3 and No. 333-224030 on Form S-8 of our report dated March 12, 2020, relating to the consolidated financial statements of Homology Medicines, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2019.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 12, 2020